<DOC>
	<DOCNO>NCT02873286</DOCNO>
	<brief_summary>A total 400 subject recruit five treatment subject group à 80 subjects.Subject receive two administration 4 week apart consist MVA-BN-RSV Dose 1 , MVA-BN-RSV Dose 2 Placebo ( TBS ) .</brief_summary>
	<brief_title>RSV-MVA-BN Vaccine Phase II Trial ≥ 55 Year Old Adults</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>sign date informed consent form HIPAA . Subjects without symptomatic cardiopulmonary and/or metabolic disease . Body mass index ( BMI ) ≥ 18.5 ≤ 39.9 . Negative human immunodeficiency virus antibody test ( antiHIV ) , HBsAG HCV virus . Electrocardiogram ( ECG ) without clinically significant acute finding . WOCBP must negative serum pregnancy test screen negative urine pregnancy test prior vaccination . pregnant breastfeed woman . History current clinical manifestation serious medical condition . History active autoimmune disease . Known suspected impairment immunologic function include , limited chronic inflammatory bowel disorder , diabetes mellitus type I. Knowledge/history allergic disease reaction likely exacerbate component vaccine . History anaphylaxis severe allergic reaction vaccine . Chronic systemic administration define 14 day &gt; 5 mg prednisone per day .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>RSV Vaccines</keyword>
	<keyword>Respiratory Syncytial Virus Vaccines</keyword>
</DOC>